Recruiting

Testing a new medication for psoriatic arthritis symptoms

Plain-English translation of NCT06807424 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated October 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a large Phase 3 trial testing , a new medication designed to treat psoriatic arthritis. Researchers are comparing the medication at two different doses against placebo to see which works best at reducing joint pain, swelling, and skin symptoms. About 750 people will participate, including some who have tried other arthritis drugs before and some who haven't.

Psoriatic arthritis can be difficult to control, and some people don't respond well to current treatments or need additional options. This trial aims to see whether this medication could offer another effective choice for people struggling with active joint and skin symptoms.

Do you qualify?

You likely qualify if…

you have been diagnosed with psoriatic arthritis for at least 3 months and meet standard diagnostic criteria
you have active symptoms right now, including at least 3 swollen joints and 3 tender joints
you have active skin plaques or nail changes typical of psoriasis
you have tried at least one other arthritis treatment (such as a non-biologic drug, apremilast, or one biologic therapy) without full control of your symptoms
you have a blood test showing inflammation (C-reactive protein level of 0.1 or higher)
if you are a woman who could become pregnant, you have a negative pregnancy test

You likely don't qualify if…

you have serious or uncontrolled problems with your kidneys, liver, heart, lungs, stomach, or other major organs
you have cancer now or have had cancer in the past 5 years
you are allergic or sensitive to icotrokinra or any of its ingredients
you have other inflammatory diseases like rheumatoid arthritis or lupus that could interfere with the study results
you have fibromyalgia or osteoarthritis symptoms that could complicate how doctors assess whether the treatment is working

What participation looks like

You will be randomly assigned to receive either the new medication at one of two doses or a placebo (dummy pill). If you get the placebo, you will switch to active medication at week 16. You will attend regular visits to have blood tests, physical exams of your joints, and assessments of your symptoms. After the main study period, you may be eligible to continue in a long-term extension where you receive the active medication to see how it works over time.

AI-generated summary from trial data · Oct 6, 2026 · Not medical advice

Trial locations(236 sites)

United States

AARA Clinical Research, Glendale, Arizona

AARA Clinical Research 1, Mesa, Arizona

Arthritis and Rheumatism Associates ARA Jonesboro, Jonesboro, Arkansas

Clinical Research of West Florida, Clearwater, Florida

Omega Research Consultants, DeBary, Florida